| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 39.48 | 4.0% |
| Total Income | 39.48 | 4.0% |
| Expenditure | 39.36 | 1.4% |
| PBT | -1.12 | 56.8% |
| Net Profit | -3.79 | 30.5% |
| OPM | 0.32% | 2.56pp |
| NPM | -9.59% | 4.78pp |
| EPS | -0.01 | 0.0% |
MariMed Reports Q1 2026 Earnings
14 May 2026 · 14 May, 2:46 am
Summary
MariMed Inc. reported its financial results for the first quarter ended March 31, 2026. The company's revenue increased to $39.5 million from $37.9 million in the prior year. GAAP Net loss was $(3.8) million, while Non-GAAP Net loss was $(3.2) million. The company's non-GAAP Adjusted EBITDA was $3.6 million, representing a 9% margin. MariMed continues to focus on disciplined capital execution, operational efficiency, and strengthening liquidity.
Key Highlights
- 1
MariMed's first quarter revenue increased year-over-year, supported by expanded wholesale distribution and retail growth.
- 2
Revenue for the first quarter ended March 31, 2026, was $39.5 million compared to $37.9 million in the prior year.
- 3
The company's non-GAAP Adjusted EBITDA for the quarter was $3.6 million, with a margin of 9%.
- 4
GAAP Net loss was $(3.8) million for the quarter ended March 31, 2026, compared to $(5.5) million for the same period in 2025.
- 5
Non-GAAP Net loss was $(3.2) million for the quarter ended March 31, 2026, compared to $(3.9) million for the same period in 2025.
- 6
The company announced a Restructuring and Exchange Agreement, eliminating the February 26, 2026 mandatory conversion date obligation.
Management Comments
Jon Levine
"The first quarter reflected MariMed's continued year-over-year growth, supported by expanded wholesale distribution, retail growth, and continued execution of our 'Expand the Brand' strategy of making our top-selling brands accessible to more people in both existing and new markets." "In an industry environment where many operators continue to face pricing compression and limited growth, MariMed continues to strengthen profitability, expand branded distribution, and reinforce the market positioning of our core brands through disciplined operational execution." "Our products maintained or grew their market-leading positions in the most popular categories across our wholesale markets, demonstrating our operational excellence across innovation, manufacturing, and sell-through. Following the recent historic rescheduling announcement and continued progress of our 2026 growth drivers, MariMed is well-positioned to capitalize on this transformative period for our industry." "We also remain focused on disciplined capital execution, operational efficiency, and strengthening liquidity while continuing to invest in high-return growth opportunities that support long-term shareholder value creation."
Informational and educational content only. Not investment advice.